HRP20190442T1 - Kapsid - Google Patents
KapsidInfo
- Publication number
- HRP20190442T1 HRP20190442T1 HRP20190442TT HRP20190442T HRP20190442T1 HR P20190442 T1 HRP20190442 T1 HR P20190442T1 HR P20190442T T HRP20190442T T HR P20190442TT HR P20190442 T HRP20190442 T HR P20190442T HR P20190442 T1 HRP20190442 T1 HR P20190442T1
- Authority
- HR
- Croatia
- Prior art keywords
- capsid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1508026.0A GB201508026D0 (en) | 2015-05-11 | 2015-05-11 | Capsid |
| PCT/GB2016/051329 WO2016181123A1 (en) | 2015-05-11 | 2016-05-10 | Capsid |
| EP16721917.9A EP3250239B1 (en) | 2015-05-11 | 2016-05-10 | Capsid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190442T1 true HRP20190442T1 (hr) | 2019-05-03 |
Family
ID=53489438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190442TT HRP20190442T1 (hr) | 2015-05-11 | 2016-05-10 | Kapsid |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10414803B2 (https=) |
| EP (2) | EP3511021A1 (https=) |
| JP (2) | JP6619454B2 (https=) |
| KR (1) | KR20180019543A (https=) |
| CN (1) | CN107864653B (https=) |
| AU (1) | AU2016261454B2 (https=) |
| CA (1) | CA2985945C (https=) |
| DK (1) | DK3250239T3 (https=) |
| ES (1) | ES2711349T3 (https=) |
| GB (1) | GB201508026D0 (https=) |
| HR (1) | HRP20190442T1 (https=) |
| HU (1) | HUE042693T2 (https=) |
| LT (1) | LT3250239T (https=) |
| PL (1) | PL3250239T3 (https=) |
| PT (1) | PT3250239T (https=) |
| TR (1) | TR201901582T4 (https=) |
| TW (1) | TW201704253A (https=) |
| WO (1) | WO2016181123A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| GB201508026D0 (en) * | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| ES2865487T3 (es) | 2015-09-28 | 2021-10-15 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores virales que evaden los anticuerpos |
| GB201608046D0 (en) | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| BR112019013245A2 (pt) | 2016-12-30 | 2020-02-11 | The Trustees Of The University Of Pennsylvania | Terapia gênica para tratamento da doença de wilson |
| EP3645021A4 (en) * | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| EP3774853A1 (en) * | 2018-03-30 | 2021-02-17 | The Board of Trustees of the Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism |
| AU2019247748A1 (en) | 2018-04-03 | 2020-10-08 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| MX2020010465A (es) | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| EP3774852A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| KR102114249B1 (ko) | 2018-08-21 | 2020-05-22 | 코나아이 (주) | 가상 화폐 결제 방법 및 시스템 |
| GB201817810D0 (en) | 2018-10-31 | 2018-12-19 | Ucl Business Plc | Modified factor IX polypeptides |
| DK3906066T5 (da) | 2019-01-04 | 2024-08-05 | Ultragenyx Pharmaceutical Inc | Geneterapikonstruktioner til behandling af wilsons sygdom |
| AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
| EP3715358A1 (en) * | 2019-03-28 | 2020-09-30 | Universität zu Köln | Mutated adeno-associated virus capsid proteins, aav particle comprising the same and liver directed aav vector gene therapy |
| KR20220019669A (ko) | 2019-04-12 | 2022-02-17 | 프리라인 테라퓨틱스 리미티드 | 플라스미드 시스템 |
| DK3722434T3 (da) | 2019-04-12 | 2022-10-24 | Freeline Therapeutics Ltd | Plasmidsystem |
| US20220265853A1 (en) * | 2019-07-12 | 2022-08-25 | Gene Therapy Research Institution Co., Ltd. | Adeno-associated virus virion for gene transfer to human liver |
| WO2021030764A1 (en) * | 2019-08-14 | 2021-02-18 | University Of Florida Research Foundation, Incorporated | Aav capsid variants for gene therapy |
| CN115087738A (zh) * | 2019-08-29 | 2022-09-20 | 小利兰·斯坦福大学托管委员会 | 用于穿越人血脑屏障的腺相关病毒载体 |
| JP2022551739A (ja) | 2019-10-17 | 2022-12-13 | ストライドバイオ，インコーポレイテッド | ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター |
| US12611436B2 (en) | 2019-10-17 | 2026-04-28 | Sarepta Therapeutics, Inc. | AAV transfer cassette |
| BR112022016965A2 (pt) * | 2020-02-25 | 2022-12-06 | Childrens Medical Res Institute | Polipeptídeos e vetores de capsídeo do vírus adenoassociado |
| CA3187635A1 (en) * | 2020-07-03 | 2022-01-06 | Genethon | Method for engineering novel hybrid aav capsids through hypervariable regions swapping |
| CN111876432B (zh) * | 2020-07-29 | 2022-10-28 | 舒泰神（北京）生物制药股份有限公司 | 一组肝靶向新型腺相关病毒的获得及其应用 |
| AU2021328475A1 (en) | 2020-08-19 | 2023-03-16 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of Rett syndrome |
| WO2022060916A1 (en) | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized antibodies for anti-viral therapy |
| WO2022060915A1 (en) | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized lanadelumab and administration thereof |
| GB202016254D0 (en) | 2020-10-13 | 2020-11-25 | Freeline Therapeutics Ltd | Plasmid system |
| WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
| CA3195967A1 (en) | 2020-10-28 | 2022-05-05 | Xu Wang | Vectorized anti-tnf-? antibodies for ocular indications |
| US20230390418A1 (en) | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| CN113121654B (zh) * | 2021-04-19 | 2023-11-17 | 信念医药科技(上海)有限公司 | 腺相关病毒衣壳蛋白及包含其的腺相关病毒载体 |
| WO2022226301A1 (en) * | 2021-04-23 | 2022-10-27 | The University Of North Carolina At Chapel Hill | Chimeric heart tropic aav capsids |
| GB202109231D0 (en) | 2021-06-25 | 2021-08-11 | Freeline Therapeutics Ltd | Promoter |
| CN118201947B (zh) * | 2021-10-28 | 2025-03-21 | 上海天泽云泰生物医药有限公司 | 腺相关病毒衣壳 |
| GB202205514D0 (en) | 2022-04-13 | 2022-05-25 | Freeline Therapeutics Ltd | Mechanical lysis |
| US20260034246A1 (en) | 2022-05-03 | 2026-02-05 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
| WO2023215807A1 (en) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS |
| GB202214328D0 (en) | 2022-09-29 | 2022-11-16 | Freeline Therapeutics Ltd | Method |
| WO2024238867A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
| WO2024238859A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized c5 inhibitor agents and administration thereof |
| WO2025087695A1 (en) | 2023-10-23 | 2025-05-01 | Ascend Advanced Therapies Ltd | Method for producing recombinant adeno-associated virus particles |
| EP4628576A1 (en) | 2024-04-07 | 2025-10-08 | Ascend Advanced Therapies GmbH | Microrna molecules for use in methods for improving recombinant aav production |
| TW202548025A (zh) | 2024-04-08 | 2025-12-16 | 美商銳進科斯生物股份有限公司 | 載體化抗補體抗體與補體劑及其投與 |
| WO2025238067A1 (en) | 2024-05-15 | 2025-11-20 | Ascend Advanced Therapies Gmbh | Novel vector system for aav production |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| EP1030861A4 (en) | 1997-10-31 | 2001-09-05 | Maxygen Inc | MODIFICATION OF VIRUSTROPISMIUS AND THE ECONOMIC SPECTRUM BY VIRAL GENOM MIXING |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| EP1026250A1 (en) | 1998-12-02 | 2000-08-09 | Aventis Behring GmbH | DNA-constructs of blood clotting factors and P-selectin |
| EP1010762A1 (en) | 1998-12-02 | 2000-06-21 | Aventis Behring Gesellschaft mit beschränkter Haftung | DNA constructs of blood clotting factors and P-Selectin |
| EP1048726B1 (en) | 1999-04-27 | 2006-07-26 | Négrier, Claude | Modified factor VIII cDNA |
| EP1038959A1 (en) | 1999-03-17 | 2000-09-27 | Aventis Behring Gesellschaft mit beschränkter Haftung | Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX |
| CA2373110A1 (en) | 2000-03-14 | 2001-09-20 | Neurologix, Inc. | Production of chimeric capsid vectors |
| US7749492B2 (en) | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| US7858367B2 (en) | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
| SI1633772T1 (sl) | 2003-06-19 | 2016-06-30 | Genzyme Corporation | AAV virioni z zmanjšano imunoreaktivnostjo in uporaba za ta namen |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| US20060166363A1 (en) | 2004-01-27 | 2006-07-27 | Sergei Zolotukhin | Modified baculovirus expression system for production of pseudotyped rAAV vector |
| JP5136766B2 (ja) | 2004-12-15 | 2013-02-06 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | キメラベクター |
| CA2610164A1 (en) | 2005-05-31 | 2006-12-07 | Neurologix, Inc. | Novel glutamic acid decarboxylase (gad) chimera and methods of use |
| US7867484B2 (en) | 2006-01-27 | 2011-01-11 | University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| ES2714007T3 (es) | 2007-04-09 | 2019-05-24 | Univ Florida | Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso |
| US9725485B2 (en) | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
| ES2602610T3 (es) | 2007-05-31 | 2017-02-21 | Medigene Ag | Proteína estructural mutada de un parvovirus |
| WO2009137006A2 (en) | 2008-04-30 | 2009-11-12 | The University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| ES2742180T3 (es) | 2009-03-04 | 2020-02-13 | Deutsches Krebsforsch | Proteína activadora del ensamblaje (AAP) y su uso para la fabricación de partículas de parvovirus que consisten esencialmente en VP3 |
| GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| CA2853482C (en) | 2011-10-28 | 2020-05-19 | Joshua Grieger | Cell line for production of adeno-associated virus |
| EP2900686B1 (en) | 2012-09-28 | 2020-06-10 | The University of North Carolina At Chapel Hill | Aav vectors targeted to oligodendrocytes |
| AU2013336601B2 (en) | 2012-10-26 | 2018-01-25 | Vrije Universiteit Brussel | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
| ES2667209T3 (es) | 2013-03-14 | 2018-05-10 | Asklepios Biopharmaceutical, Inc. | Genes del receptor-1 de VEGF soluble modificado y vectores para terapia génica |
| ES2926774T3 (es) | 2013-03-15 | 2022-10-28 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores AAV de doble unión de glicano |
| EP3492597A3 (en) | 2013-05-21 | 2019-08-28 | University of Florida Research Foundation, Inc. | Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer |
| IL297919A (en) | 2013-07-22 | 2023-01-01 | Childrens Hospital Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| SI3702466T1 (sl) | 2013-08-27 | 2023-04-28 | Research Institute At Nationwide Children's Hospital | Proizvodi in postopki za zdravljenje amiotrofične lateralne skleroze |
| CN106232618A (zh) * | 2013-10-11 | 2016-12-14 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| US20170007720A1 (en) | 2014-02-21 | 2017-01-12 | University Of Florida Research Foundation, Inc. | Methods and compositions for gene delivery to on bipolar cells |
| EP3113787B1 (en) | 2014-03-04 | 2019-12-04 | University of Florida Research Foundation, Inc. | Improved raav vectors and methods for transduction of photoreceptors and rpe cells |
| CN114395559A (zh) | 2014-04-25 | 2022-04-26 | 吉尼松公司 | 高胆红素血症的治疗 |
| LT3137497T (lt) | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CN107073051B (zh) | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | 重组aav变体及其用途 |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| EP4344741A3 (en) | 2014-11-21 | 2024-08-28 | The University of North Carolina at Chapel Hill | Aav vectors targeted to the central nervous system |
| GB201502137D0 (en) | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
| WO2016133917A1 (en) | 2015-02-16 | 2016-08-25 | University Of Florida Research Foundation | Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes |
| WO2016137949A1 (en) | 2015-02-23 | 2016-09-01 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| US11021519B2 (en) | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| JP6836999B2 (ja) | 2015-03-24 | 2021-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | アデノ随伴ウイルス変異体及びその使用方法 |
| US10081659B2 (en) | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
| EP3285788B1 (en) | 2015-04-23 | 2024-12-18 | University of Massachusetts | Modulation of aav vector transgene expression |
| GB201508026D0 (en) * | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| MX390848B (es) | 2015-06-23 | 2025-03-21 | Childrens Hospital Philadelphia | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. |
| WO2017015102A1 (en) | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for achieving high levels of transduction in human liver cells |
| US20190000940A1 (en) | 2015-07-31 | 2019-01-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of aadc deficiency |
| ES2865487T3 (es) | 2015-09-28 | 2021-10-15 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores virales que evaden los anticuerpos |
| WO2017066764A2 (en) | 2015-10-16 | 2017-04-20 | William Marsh Rice University | Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses |
| WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| MX2018004755A (es) | 2015-10-29 | 2018-12-19 | Voyager Therapeutics Inc | Entrega de polinucleotidos dirigidos al sistema nervioso central. |
| PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| SG11201802408RA (en) | 2015-11-05 | 2018-05-30 | Bamboo Therapeutics Inc | Modified friedreich ataxia genes and vectors for gene therapy |
| EP3384034B1 (en) | 2015-12-02 | 2020-07-08 | The Board of Trustees of the Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
| US10406244B2 (en) | 2015-12-02 | 2019-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | AAV vectors with expanded packaging capacity |
| KR102423442B1 (ko) | 2015-12-11 | 2022-07-20 | 캘리포니아 인스티튜트 오브 테크놀로지 | 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드 |
| JP7406783B2 (ja) | 2015-12-14 | 2023-12-28 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質 |
| JP6947739B2 (ja) | 2016-02-16 | 2021-10-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 既存のヒト中和抗体に対して耐性である新規組換えアデノ随伴ウイルスカプシド |
| WO2017161273A1 (en) | 2016-03-18 | 2017-09-21 | The Children's Hospital Of Philadelphia | Therapeutic for treatment of diseases including the central nervous system |
| US11433116B2 (en) | 2016-04-14 | 2022-09-06 | Cedars-Sinai Medical Center | GJA1 isoforms protect against metabolic stress |
| US20190224339A1 (en) | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| CN109843913B (zh) | 2016-06-16 | 2024-03-08 | 柏林夏洛特医科大学 | 神经肽表达载体以及用于治疗癫痫的方法 |
| IL305149A (en) | 2016-07-26 | 2023-10-01 | Biomarin Pharm Inc | Novel adeno-associated virus capsid proteins |
| CA3033856A1 (en) | 2016-08-15 | 2018-02-22 | Genzyme Corporation | Methods for detecting aav |
| JP7610923B2 (ja) | 2016-09-02 | 2025-01-09 | スパーク セラピューティクス インコーポレイテッド | Ｃｎｓ障害を治療するための方法及びベクター |
| WO2018046774A1 (en) | 2016-09-12 | 2018-03-15 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293203A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293259A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| AU2017347854B2 (en) | 2016-10-27 | 2022-12-08 | Intima Bioscience, Inc. | Viral methods of T cell therapy |
| US11905312B2 (en) | 2017-02-15 | 2024-02-20 | The University Of North Carolina At Chapel Hill | Methods and compositions for gene transfer across the vasculature |
| WO2018162748A1 (en) | 2017-03-10 | 2018-09-13 | Genethon | Treatment of glycogen storage disease iii |
| NZ756587A (en) | 2017-03-15 | 2025-12-19 | Univ North Carolina Chapel Hill | Polyploid adeno-associated virus vectors and methods of making and using the same |
| EP3609542B1 (en) | 2017-04-11 | 2023-02-22 | Ruprecht-Karls-Universität Heidelberg | Adeno-associated virus library |
| WO2018200419A1 (en) | 2017-04-23 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | Viral vectors comprising engineered aav capsids and compositions containing the same |
| JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| WO2018226887A1 (en) | 2017-06-07 | 2018-12-13 | Spark Therapeutics, Inc. | ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| PE20200737A1 (es) | 2017-06-30 | 2020-07-23 | Spark Therapeutics Inc | Metodos de purificacion de columna de vector aav |
| SG11202000840YA (en) | 2017-07-31 | 2020-02-27 | Reflection Biotechnologies Ltd | Cellular models of and therapies for ocular diseases |
| PE20200722A1 (es) | 2017-08-01 | 2020-07-21 | Spark Therapeutics Inc | Metodos de terapia genica del factor viii (fviii) |
| EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| EP3676284A1 (en) | 2017-08-29 | 2020-07-08 | Ruprecht-Karls-Universität Heidelberg | Rationally designed virus-like particles for modulation of chimeric antigen receptor (car)-t-cell therapy |
| US20200377887A1 (en) | 2017-09-22 | 2020-12-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| US12123027B2 (en) | 2017-10-12 | 2024-10-22 | Ascend Advanced Therapies Limited | Life-cycle-defective adenovirus helper viruses, their production and use for producing rAAV |
-
2015
- 2015-05-11 GB GBGB1508026.0A patent/GB201508026D0/en not_active Ceased
-
2016
- 2016-05-10 WO PCT/GB2016/051329 patent/WO2016181123A1/en not_active Ceased
- 2016-05-10 HR HRP20190442TT patent/HRP20190442T1/hr unknown
- 2016-05-10 AU AU2016261454A patent/AU2016261454B2/en active Active
- 2016-05-10 CN CN201680027100.0A patent/CN107864653B/zh active Active
- 2016-05-10 CA CA2985945A patent/CA2985945C/en active Active
- 2016-05-10 ES ES16721917T patent/ES2711349T3/es active Active
- 2016-05-10 PT PT16721917T patent/PT3250239T/pt unknown
- 2016-05-10 PL PL16721917T patent/PL3250239T3/pl unknown
- 2016-05-10 EP EP18210522.1A patent/EP3511021A1/en active Pending
- 2016-05-10 EP EP16721917.9A patent/EP3250239B1/en active Active
- 2016-05-10 TR TR2019/01582T patent/TR201901582T4/tr unknown
- 2016-05-10 US US15/573,350 patent/US10414803B2/en active Active
- 2016-05-10 HU HUE16721917A patent/HUE042693T2/hu unknown
- 2016-05-10 DK DK16721917.9T patent/DK3250239T3/en active
- 2016-05-10 KR KR1020177035515A patent/KR20180019543A/ko not_active Ceased
- 2016-05-10 JP JP2017558723A patent/JP6619454B2/ja active Active
- 2016-05-10 LT LTEP16721917.9T patent/LT3250239T/lt unknown
- 2016-05-11 TW TW105114580A patent/TW201704253A/zh unknown
-
2019
- 2019-08-15 US US16/541,516 patent/US12138318B2/en active Active
- 2019-11-14 JP JP2019206191A patent/JP2020096587A/ja active Pending
-
2024
- 2024-10-09 US US18/911,006 patent/US20250127922A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2985945C (en) | 2022-09-06 |
| EP3511021A1 (en) | 2019-07-17 |
| US20250127922A1 (en) | 2025-04-24 |
| CN107864653A (zh) | 2018-03-30 |
| JP6619454B2 (ja) | 2019-12-11 |
| EP3250239B1 (en) | 2018-12-12 |
| TR201901582T4 (tr) | 2019-02-21 |
| US10414803B2 (en) | 2019-09-17 |
| LT3250239T (lt) | 2019-03-25 |
| PT3250239T (pt) | 2019-02-19 |
| CA2985945A1 (en) | 2016-11-17 |
| JP2018520997A (ja) | 2018-08-02 |
| AU2016261454A1 (en) | 2017-11-23 |
| PL3250239T3 (pl) | 2019-05-31 |
| US20200079821A1 (en) | 2020-03-12 |
| CN107864653B (zh) | 2022-06-21 |
| HUE042693T2 (hu) | 2019-07-29 |
| AU2016261454B2 (en) | 2019-07-11 |
| US20180111965A1 (en) | 2018-04-26 |
| US12138318B2 (en) | 2024-11-12 |
| GB201508026D0 (en) | 2015-06-24 |
| JP2020096587A (ja) | 2020-06-25 |
| TW201704253A (zh) | 2017-02-01 |
| ES2711349T3 (es) | 2019-05-03 |
| EP3250239A1 (en) | 2017-12-06 |
| WO2016181123A1 (en) | 2016-11-17 |
| DK3250239T3 (en) | 2019-03-11 |
| KR20180019543A (ko) | 2018-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE042693T2 (hu) | Kapszid | |
| DK3283625T3 (da) | Nukleasemedieret genomeditering | |
| EP3286361A4 (en) | Cancer neoepitopes | |
| DK3331869T3 (da) | Muscarinagonister | |
| DK3331528T3 (da) | Muskarinagonister | |
| DK3277719T3 (da) | Polypeptider | |
| EP3316375A4 (en) | Redox flow cell | |
| DK3360890T3 (da) | Genterapi | |
| DK3305788T3 (da) | Janus-kinase-hæmmer | |
| DK3331529T3 (da) | Muskarinagonister | |
| EP3290364A4 (en) | Conveyor belt wear monitoring system | |
| DK3310450T3 (da) | Olie-vand-separator | |
| DK3394281T3 (da) | Gærcelle | |
| DK3270930T3 (da) | Præeklampsi | |
| EP3381654A4 (en) | Liquid blow molding method | |
| EP3393959A4 (en) | GRAB | |
| EP3363322A4 (en) | Hair extender | |
| DK3292136T3 (da) | Penicillin-g-acylaser | |
| DK3274482T3 (da) | Stenborsknop | |
| DE112015006486A5 (de) | Inkubationsrinne | |
| EP3390373C0 (en) | DOTA SUMMARY | |
| EP3548009A4 (en) | POLYMERIC NANOPARTICLES | |
| EP3377179A4 (en) | DEUTERED EPI-743 | |
| DK3318308T3 (da) | Badmintonketsjer | |
| DE102015206660A8 (de) | Plattenaufteilanlage |